82.
83. Impact of the Ice Bucket Challenge. ALS Association. www.alsa.org/ fight-als/ibc-infographic.html. Accessed February 8, 2019.
84. ACT UP New York. www.actupny.org. Accessed March 30, 2019.
85. ParkinsonNet. www.parkinsonnet.info. Accessed January 5, 2019.
86. Okun MS, Ramirez-Zamora A, Foote KD. Neuromedicine service and science hub model.
87. Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands.
88. van der Kolk NM, de Vries NM, Penko AL, et al. A remotely supervised home-based aerobic exercise programme is feasible for patients with Parkinson’s disease: results of a small randomised feasibility trial.
89. Szanton SL, Leff B, Wolff JL, Roberts L, Gitlin LN. Home-based care program reduces disability and promotes aging in place.
90. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson’s disease using the minimum data set.
91. Centers for Medicare & Medicaid Services. Medicare & Home Health Care. US Department of Health and Human Services. October 2017. www.medicare.gov/sites/default/files/2018-07/10969-medicare-and-home-health-care.pdf; Your Medicare coverage. Medicare.gov. www. medicare.gov/coverage/home-health-services. Accessed March 30, 2019.
92. Woods B. By 2020, 90 % of world’s population aged over 6 will have a mobile phone: report. The Next Web. November 18, 2014. https:// thenextweb.com/insider/2014/11/18/2020-90-worlds-population-aged-6-will-mobile-phone-report. Accessed October 11, 2018.
93. Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care.
94. WHO Model List of Essential Medicines. World Health Organization; April 2015.
95. Clinical trial delays: America’s patient recruitment dilemma. Drug Development Technology. July 18, 2012. www.drugdevelopment-technology.com/features/featureclinical-trial-patient-recruitment. Accessed March 30, 2019.
96. Fox Trial Finder. The Michael J. Fox Foundation for Parkinson’s Research. https://foxtrialfinder.michaeljfox.org. Accessed March 30, 2019.
97. Why Clinical Trials? The Michael J. Fox Foundation for Parkinson’s Research.https://files.michaeljfox.org/WhyClinicalTrials.pdf. Accessed January 3, 2019; Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC. Minority enrollment in Parkinson’s disease clinical trials.
98. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit.
99. Fox Insight. The Michael J. Fox Foundation for Parkinson’s Research. https://foxinsight.michaeljfox.org. Accessed January 6, 2019.
100. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease.
101. P earson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service.
102. Weintraub A. How to cover Novartis’ $475K CAR-T drug Kymriah? A “new payment model” is the only way, Express Scripts says. FiercePharma. September 22, 2017. www.fiercepharma.com/financials/ car-t-and-other-gene-therapies-need-new-payment-model-says-express-scripts. Accessed January 6, 2019; Rosenblatt M, Termeer H. Reframing the conversation on drug pricing.